All
- All
- Articles
- Calendar
- Compliance
- Newsletter
- Position Statements
- Press Release
- Regulatory
- Uncategorized
FDA Issues Warning Letters Alleging Unapproved New Drug Status and CGMP Non-Compliance
By Alvin J. Lorman, AAHP Counsel The Food and Drug Administration (FDA) has issued two Warning Letters that should be of intertest to all manufacturers...
Quality by Design
By Mark Land, M.S., RAC-US, AAHP Quality by Design (QbD) is a systematic approach to product and process development that begins with predefined objectives and...
Supplier Audits
By Jonathan Priest The Quality by Design (QbD) approach of today's pharmaceutical industry indicates that all firms should perform supplier audits for drug product components...
10 Q&A on Homeopathy
Complied here is a brief fact sheet that AAHP uses when introducing homeopathy to Congressional health staff on Capitol Hill. More robust information can be...
Helpful Tips to Answer Common Questions (Fighting Misperceptions)
By Mark Land, M.S., RAC-US, AAHP Answering common questions or "frequently asked questions" (FAQs) is an engagement concept that probably dates back forever. The goal...
Maturing of Research in Homeopathy Seen at 2025 HRI Conference
By Mark Land, M.S., RAC-US, AAHP President This June, the Homeopathy Research Institute hosted its 6th international research conference on homeopathy and, for the second...
Highlights of the 2025 Homeopathic Research Institute Conference in Greece
AAHP's picks from attending and from the HRI Conference Booklet The Homeopathy Research Institute (HRI) held its 6th international research conference on homeopathy in Thessaloniki,...
